Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

Abbvie image

AbbVie hep C treatment fast-tracked

June 18, 2014
Research and Development, Sales and Marketing AbbVie, Abbott, EMA, EU, Gilead, HCV, hep C, sovaldi

The European regulator is to fast-track AbbVie’s oral, interferon-free treatment for adults with chronic genotype 1 (GT1) hepatitis C virus …

News
gilead_-sciences

NICE rejection looms for Sovaldi

June 16, 2014
Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi

In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …

News
Sovaldi image

Sovaldi hurdles first drug pricing barrier

June 10, 2014
Sales and Marketing Gilead, SMC, Scotland, hep C, sofosbuvir, sovaldi

Scotland’s NHS will pay for Gilead’s new hepatitis C pill Sovaldi despite rising concern over its high cost. The Scottish …

News

Sales forecasts leave Sovaldi top and Januvia lagging

May 23, 2014
Sales and Marketing Gilead, Januvia, Merck, diabetes, ep, hep C, sovaldi

Sovaldi has topped analysts’ estimates for future growth but Merck’s big-selling diabetes drug Januvia is falling by the wayside. This …

News
Sovaldi pack shot

Gilead price lambasted by US health insurers

May 21, 2014
Medical Communications, Sales and Marketing Gilead, Incivek, Victrelis, hepatitis C, sovaldi

Gilead’s new hepatitis C pill Sovaldi is coming under more pressure in the US as health insurers hit out at …

News
sovaldi iamge

Sovaldi performs for Gilead

April 24, 2014
Sales and Marketing Gilead, HCV, Q1, hepatitis C, sovaldi

Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has returned better than expected figures in the first quarter of the …

News
Biocon image

Novartis sues Biocon

April 4, 2014
Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir

India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …

News
GSK image

CHMP breathes new life into GSK, Teva and Novartis

February 24, 2014
Research and Development, Sales and Marketing CHMP, COPD, EMA, GSK, Gilead, Teva, asthma, onoro

The CHMP has given its backing to a number of new treatments for respiratory diseases, which include two from London-based …

News
Gilead image

‘Compassionate’ use of hep C combo

February 24, 2014
Research and Development, Sales and Marketing CHMP, EMA, Gilead, hep C, ledipasvir, sovaldi

A key adviser to the European regulator has said that Gilead Sciences’ fixed-dose combination of Sovaldi and ledipasvir can be …

News
gsk_through_window

Pharma’s reputation ‘getting worse’

February 17, 2014
Medical Communications, Sales and Marketing GSK, Gilead, Pfizer, ViiV, patientview, pharma, reputation

The pharma industry’s reputation is getting worse – at least, in the eyes of 800 patient groups – according to …

News
Sovaldi image

Gilead to allow cheaper generics of new hep C drug

February 6, 2014
Manufacturing and Production, Sales and Marketing Gilead, India, generics, hep C, s&m, sofosbuvir, sovaldi

Gilead has announced the unusual step of allowing its new and highly expensive hepatitis C pill to be sold as …

News

Europe nod for Gilead HCV pill

January 20, 2014
Sales and Marketing FDA, Gilead, HCV, hep C, sofosbuvir, sovaldi

Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has been given the green light by the European Commission, just a …

News
Abbvie image

AbbVie posts strong results for Hep C pill

December 11, 2013
Research and Development, Sales and Marketing 3D, AbbVie, FDA, Gilead, hep C

AbbVie’s investigational hepatitis C pill cured 96% of difficult-to-treat patients in a late-stage clinical trial and looks set to muscle …

News
sovaldi image

Gilead’s $1,000 per day Hep C drug approved

December 9, 2013
Sales and Marketing FDA, Gilead, hepc, sofosbuvir, sovaldi

Gilead’s Sovaldi has gained FDA approval as a potential cure for hepatitis C after the US regulator sped up its …

News
Gilead image

Gilead runs into India patent trouble

November 26, 2013
Sales and Marketing Gilead, MSF, hepc, sofosbuvir, sovaldi

Gilead Sciences has run into heavy traffic in India as campaigners attempt to block the company’s patent there on new …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025